DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Heizer WD, Peterson JL. Acute myeloblastic leukemia following
prolonged treatment of Crohn’s disease with 6-mercaptopurine.
Dig Dis Sci, 1998, 43:1791–1793.
Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis:
15 years experience. Am J Med, 1983, 75:69–73.
Hogan TF, Citrin DL, Johnson BM, et al. o,p′-DDD (mitotane)
therapy of adrenal cortical carcinoma: Observations on drug
dosage, toxicity, and steroid replacement. Cancer, 1978,
42:2177–2181.
Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of
paclitaxel and metabolites in a randomized comparative study
in platinum-pretreated ovarian cancer patients. J Clin Oncol,
1993, 11:2127–2135.
Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabineassociated
thrombotic microangiopathy. Cancer, 2004,
100:2664–2670.
Ibrado AM, Huang Y, Fang G, Bhalla K. Bcl-xL overexpression
inhibits taxol-induced Yama protease activity and apoptosis.
Cell Growth Differ, 1996, 7:1087–1094.
Iyer L, King CD, Whitington PF, et al. Genetic predisposition to
the metabolism of irinotecan (CPT-11). Role of uridine diphosphate
glucuronosyltransferase isoform 1A1 in the glucuronidation
of its active metabolite (SN-38) in human liver microsomes.
J Clin Invest, 1998, 101:847–854.
Jabbour E, O’Brien S, Kantarjian H, et al. Neurologic complications
associated with intrathecal liposomal cytarabine given
prophylactically in combination with high-dose methotrexate
and cytarabine to patients with acute lymphocytic leukemia.
Blood, 2007, 109:3214–3218.
Josting A, Reiser M, Wickramanayake PD, et al. Dexamethasone,
carmustine, etoposide, cytarabine, and melphalan (dexa-
BEAM) followed by high-dose chemotherapy and stem cell
rescue—A highly effective regimen for patients with refractory
or relapsed indolent lymphoma. Leuk Lymphoma, 2000,
37:115–123.
Kamiya K, Huang P, Plunkett W. Inhibition of the 3′→5′ exonuclease
human DNA polymerase by fludarabine-terminated
DNA. J Biol Chem, 1996, 271:19428–19435.
Karran P, Attard N. Thiopurines in current medical practice:
Molecular mechanisms and contributions to therapy-related
cancer. Nat Rev Cancer, 2008, 8:24–36.
Kastan MB. Molecular determinants of sensitivity to antitumor
agents. Biochem Biophys Acta, 1999, 1424:R37–R42.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion
of chemotherapy after resection of hepatic metastases from
colorectal cancer. N Engl J Med, 1999, 341:2039–2048.
Kidd JG. Regression of transplanted lymphomas induced in vivo
by means of normal guinea pig serum. 1. Course of transplanted
cancers of various kinds in mice and rats given guinea
pig serum, horse serum, or rabbit serum. J Exp Med, 1953,
98:565–582.
Kitamura T. Necessity of re-evaluation of estramustine phosphate
sodium (EMP) as a treatment option for first-line monotherapy
in advanced prostate cancer. Int J Urol, 2001, 8:33–36.
Koolen SLW, Huitema ADR, Jansen RS, et al. Pharmacokinetics
of gemcitabine and metabolites in a patient with double-sided
nephrectomy: A case report and review of the literature.
Oncologist, 2009, 14:944–948.
Kos R, Wilding J. SPARC: a key player in the pathologies associated
with obesity and diabetes. Nat Rev Endocrinol, 2010,
6:225–235.
Kramer OH, Knauer SK, Zimmerman D, et al. Histone deacetylase
inhibitors and hydroxyurea modulate the cell cycle and
cooperatively induce apoptosis. Oncogene, 2008, 27:732–740.
Kruh GD. Lustrous insights into cisplatin accumulation: Copper
transporters. Clin Cancer Res, 2003, 9:5807–5809.
Krzakowski M, Provencio M, Utracka-Hutka B, et al. Oral
vinorelbine and cisplatin as induction chemotherapy and concomitant
chemoradiotherapy in stage III non-small cell lung
cancer: Final results of an international phase II trial. J Thorac
Oncol, 2008, 3:994–1002.
Kufe DW, Munroe D, Herrick D, et al. Effects of 1-β-D-arabinofuranosylcytosine
incorporation on eukaryotic DNA template
function. Mol Pharmacol, 1984, 26:128–134.
Kumkhaek C, Taylor JG 6th, Zhu J, et al. Fetal haemoglobin
response to hydroxycarbamide treatment and sar1a promoter
polymorphisms in sickle cell anaemia. Br J Haematol, 2008,
141:254–259.
Kuznetsov D, Alsikafi N, O’Connor R, Steinberg G. Intravesicular
valrubicin in the treatment of carcinoma in situ of the bladder.
Expert Opin Pharmacother, 2001, 2:1009–1013.
Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic
degrades PML or PML-RARalpha through a SUMO-triggered
RNF4/ubiquitin-mediated pathway. Nat Cell Biol, 2008,
10:547–555.
Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine
kinase: Identification and characterization of novel
genetic variants. J Pharmacol Exp Ther, 2007, 323: 935–945.
Lee JJ, Swain SM. The epothilones: Translating from the laboratory
to the clinic. Clin Cancer Res, 2008, 14:1618–1624.
Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda)
displays a distinct pattern of cytotoxicity and unique mechanistic
features compared with other alkylating agents. Clin
Cancer Res, 2008, 14:309–317.
Lerner HJ. Acute myelogenous leukemia in patients receiving
chlorambucil as long-term adjuvant chemotherapy for stage II
breast cancer. Cancer Treat Rep, 1978, 62:1135–1138.
Liau S, Whang E. HMGA1 is a molecular determinant of
chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Clin Cancer Res, 2008, 14:1284–1285.
Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-
2′-deoxyadenosine in humans. Cancer Res, 1991, 51:
5570–5572.
Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane
on myocardial injury in doxorubicin-treated children with
acute lymphoblastic leukemia. N Engl J Med, 2004, 351:
145–153.
Liu J, Lu Y, Wu Q, et al. Mineral arsenicals in traditional medicines:
Orpiment, realgar, and arsenolite. J Pharmacol Exp
Ther, 2008, 326:363–368.
Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent
apoptosis modulates the cytotoxicity of anticancer agents.
Cell, 1993, 74:957–967.
Ludlum DB. DNA alkylation by the haloethylnitrosoureas:
Nature of modifications produced and their enzymatic repair
or removal. Mutat Res, 1990, 233:117–126.
Mann G, Steiner M, Attarbaschi A. Clinical significance of antiasparaginase
antibodies in childhood acute lymphoblastic
leukemia. Leuk Lymphoma, 2007, 48:849–850.
Mansson E, Flordal E, Liliemark J, et al. Down-regulation of
deoxycytidine kinase in human leukemic cell lines resistant to
cladribine and clofarabine and increased ribonucleotide
1727
CHAPTER 61
CYTOTOXIC AGENTS